Last updated: April 26, 2026
Who supplies Xhance (fluticasone propionate) and how is the supply chain structured?
Xhance is a branded, drug-device combination product: fluticasone propionate nasal spray in a breath-actuated delivery device. Commercial supply is organized around (1) drug substance (fluticasone propionate) manufacturing, (2) drug product (formulation and filling into the device-compatible container) manufacturing, and (3) device manufacturing and assembly. Publicly actionable sourcing terms for each element typically come from regulatory filings (e.g., FDA CDER databases, Orange Book references, and device-specific manufacturing references), procurement disclosures, and quality agreements.
What are the known supplier roles for Xhance supply?
Because “supplier” can mean multiple things (active ingredient, finished dose, or device assembly), the supply chain is best mapped by function:
| Supply chain function |
What the supplier does |
Typical documentation where named |
| Fluticasone propionate (API) supplier |
Manufactures the active ingredient |
FDA API/manufacturing references in labeling and CMC sections; DMF references where applicable |
| Finished dose manufacturer |
Produces the drug product and fills it for the delivery system |
FDA drug product manufacturing site(s) in application/labeling |
| Device manufacturer |
Produces the breath-actuated nasal delivery device components |
Device descriptions in regulatory submissions and labeling; 510(k) is often used for device parts, but combination product structure drives what is publicly tied |
| Assembly and labeling packer |
Integrates device with drug, kits cartons, and releases lots |
Batch release references in regulatory and quality documentation; sometimes listed in labeling as manufacturer/packer |
Which company supplies Xhance as the marketed product?
Xhance is marketed in the U.S. under the brand by NextWave Pharmaceuticals, Inc. (brand authorization holder for Xhance in U.S. distribution). The supply chain is then executed through third-party manufacturers for API, drug product, and device integration under cGMP.
Who manufactures the Xhance drug product and device components?
The publicly citable answer depends on pinpointing the exact U.S. application number, listed manufacturing site(s), and combination-product assembly responsibility. In public-facing sources, those are typically captured in:
- FDA Orange Book listing for Xhance (drug product listing that links to application and sometimes manufacturing info)
- FDA labeling “Manufactured for” / “Distributed by” sections
- FDA CMC/manufacturing site references within application dossiers (not always fully public)
At this time, providing names of specific contract manufacturers (API and drug product plants) for Xhance without verified linkage to an authoritative regulatory entry would be inaccurate.
What can be stated with sourcing certainty from public regulatory structure?
Even when individual site names are not fully extractable from a single public line item, the supply structure for Xhance is consistent with combination nasal delivery products:
- API manufacturing: fluticasone propionate is produced under DMF-linked or directly listed manufacturing arrangements.
- Formulation and fill: the liquid formulation is produced and filled into a container compatible with the breath-actuated device.
- Device integration: the breath-actuated components are manufactured and then assembled with the filled container.
- Finished-goods release: final assembly, packaging, and lot release happen at labeled manufacturing/packer sites.
How do investors and R&D buyers verify “who the suppliers are” for Xhance?
In practice, the fastest verification path is to trace the product through authoritative FDA product identifiers:
- Use the Orange Book record for the Xhance active ingredient (fluticasone propionate) to obtain the application reference and identify listed dosage form details.
- Use FDA labeling to pull the “Manufactured for” and “Distributed by” language, which often maps to the final packer/releaser.
- Use the application’s manufacturing site(s) referenced in FDA submissions or publicly accessible labeling/manufacturing sections.
This method identifies suppliers at each node with citable precision instead of relying on non-regulatory marketing claims.
What suppliers matter most for risk and continuity?
For business decisions, the key dependency points are:
| Decision driver |
Supplier node that matters |
Failure mode if supplier changes |
| Shortage / continuity |
Final assembly and lot release site |
Delays in integrated product build and QMS release |
| Cost and scale |
Formulation/fill manufacturer |
Backlog in fill-finish capacity and batch definition changes |
| CMC transfer risk |
API manufacturer |
Changes in impurity profile and analytical bridging requirements |
| Quality/regulatory risk |
Device integration supplier |
Variation in actuation performance affecting dose delivery consistency |
Key Takeaways
- Xhance is a combination nasal spray with device-dependent delivery, so “supplier” must be defined by function: API, drug product (fill-finish), and device integration/assembly.
- The U.S. brand is associated with NextWave Pharmaceuticals, Inc. as the marketing entity; manufacturing and assembly typically occur via third-party cGMP partners.
- The only reliable way to list specific supplier names is to trace the FDA Orange Book record and labeling/manufacturing references tied to the exact application for Xhance and its device-integrated dosage form.
FAQs
-
What does “supplier” mean for Xhance?
It usually means API manufacturer, drug product fill-finish manufacturer, and device integration/assembly and lot release site.
-
Is Xhance only a drug manufacturer supplier or also a device supplier?
It requires both, because the product is a drug-device combination with a breath-actuated delivery device.
-
Where do the most citable supplier names come from?
FDA product listings and labeling that identify manufacturing/packing entities tied to the Xhance application and dosage form.
-
Why can’t a single “manufacturer” line be enough?
Combination products often have separate sites for API, formulation/fill, device components, and final assembly.
-
What supplier changes create the biggest regulatory or operational risk?
Final assembly/lot release, fill-finish manufacturing, and API source changes, because they can trigger CMC comparability work.
References (APA)
[1] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] U.S. Food and Drug Administration. Drug Labeling (access via DailyMed and FDA labeling repositories).
